Inflammation enhances cardiovascular risk and mortality in hemodialysis patients

Kidney International

Volumn 55, Issue 2, 1999, Pages 648-658

  Zimmermann, Josef ^a   Herrlinger, Silke ^a   Pruy, Antje ^a   Metzger, Thomas ^a   Wanner, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Acute phase response; Albumin; Apolipoprotein; Atherosclerosis; C reactive protein; Fibrinogen; Lipids; Lipoprotein(a); Mortality

Indexed keywords

AMYLOID; APOLIPOPROTEIN; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; DISEASE SEVERITY; FOLLOW UP; HEMODIALYSIS; HUMAN; HYPOTHESIS; INFLAMMATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

EID: 0032935896     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00273.x     Document Type: Article

References (50)

1. 1. ATTMAN P-O, ALAUPOVIC P: Lipid and apolipoprotein profiles of uremic dyslipoproteinemia: Relation to renal function and dialysis. Nephron 57:401-410, 1991
2. 2. ATTMAN P-O, ALAUPOVIC P, TAVELLA M, KNIGHT-GIBSON C: Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure. Nephrol Dial Transplant 11:63-69, 1996
3. 3. ASSMANN G, SCHULTE H, VON ECKARDSTEIN A: Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 77:1179-1184, 1996
4. 4. SANDKAMP M, FUNKE H, SCHULTE H, KÖHLER E, ASSMANN G: Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem 36:20-23, 1990
5. 5. BARTENS W, NAUCK M, SCHOLLMEYER P, WANNER C: Elevated lipoprotein(a) and fibrinogen serum levels increase the cardiovascular risk in CAPD patients. Perit Dial Int 16:27-33, 1996
6. 6. CRESSMAN MD, HEYKA RJ, PAGANINI EP, O'NEIL J, SKIBINSKI CI, HOFF HF: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation 86:475-482, 1992
7. 7. DIEPLINGER H, LACKNER C, KRONENBERG F, SANDHOLZER C, LHOTTA K, HOPPICHLER F, GRAF H, KÖNIG P: Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a). J Clin Invest 91:397-401, 1993
8. 8. KRONENBERG F, KÖNIG P, NEYER U, AUINGER M, PRIBASNIG A, LANG U, REITINGER J, PINTER G, UTERMANN G, DIEPLINGER H: Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6:110-120, 1995
9. 9. MAEDA S, ABE A, SEISHIMA M, MAKINO K, NOMA A, KAWADE M: Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 78:145-150, 1989
10. 10. YANG WS, KIM SB, MIN WK, PARK S, LEE MS, PARK JS: Atherogenic lipid profile and lipoprotein(a) in relation to serum albumin in haemodialysis patients. Nephrol Dial Transplant 10:1668-1671, 1995
11. 11. ERNST E: Fibrinogen: Its emerging role as a cardiovascular risk factor. Angiology 45:87-93, 1994
12. 12. KOCH M, KUTKUHN B, GRABENSEE B, RITZ E: Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: A prospective study in 412 subjects. Nephrol Dial Transplant 12:2603-2611, 1997
13. 13. KOCH M, KUTKUHN B, TRENKWALDER E, BACH D, GRABENSEE B, DIEPLINGER H, KRONENBERG F: Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 8:1889-1898, 1997
14. 14. TOMURA S, NAKAMURA Y, DOI M, ANDO R, IDA T, CHIDA Y, OOTSUKA S, SHINODA T, YANAGI H, TSUCHIYA S, MARUMO F: Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 27:848-854, 1996
15. 15. VAZIRI ND, GONZAKES EC, WANG J, SAID S: Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: Effect of hemodialysis. Am J Kidney Dis 23:828-835, 1994
16. 16. SAMMALKORPI KT, VALTONEN VV, MAURY CPJ: Lipoproteins and acute phase response during acute infection: Interrelationships between C-reactive protein and serum amyloid A protein and lipoproteins. Ann Med 22:397-401, 1990
17. 17. SLUNGA L, JOHNSON O, DAHLÉN GH, ERIKSSON S: Lipoprotein(a) and acute-phase proteins in acute myocardial infarction. Scand J Clin Lab Invest 52:95-101, 1992
18. 18. RIDKER PM, CUSHMAN M, STAMPFER MJ, TRACY RP, HENNEKENS CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336:973-979, 1997; erratum, N Engl J Med 336:973-979, 1997
19. 19. BERGSTRÖM J, HEIMBÜRGER O, LINDHOLM B, QURESHI AR: Elevated serum C-reactive protein is a strong predictor of increased mortality and low serum albumin in hemodialysis (HD) patients, (abstract) J Am Soc Nephrol 6:573, 1995
20. 20. DUBOIS DY, MALMENDIER CL: Non-competitive enzyme-linked immunosorbent assay for human apolipoprotein SAA or S. J Immunol Methods 112:71-75, 1988
21. 21. WANNER C, RADER D, BARTENS W, KRÄMER J, BREWER HB, SCHOLLMEYER P, WIELAND H: Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome. Ann Intern Med 119:263-269, 1993
22. 22. OWEN WF JR, LEW NL, LIU Y, LOWRIE EG, LAZARUS JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329:1001-1006, 1993
23. 23. KAYSEN GA, STEVENSON FT, DEPNER TA: Determinants of albumin concentration in hemodialysis patients. Am J Kidney Dis 29:659-668, 1997
24. 24. QURESHI AR, ALVESTRAND A, DANIELSSON A, DIVINO-FILHO JC, GUTIERREZ A, LINDHOLM B, BERGSTRÖM J: Factors predicting malnutrition in hemodialysis patients: A cross-sectional study. Kidney Int 53:773-782, 1998
25. 25. LINDNER A, CHARRA B, SHERRAR DJ, SCRIBNER BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290:697-701, 1974
26. 26. STAND SG, BRUNZELL JD, CANNON RO III, VICTOR RG: Cardiovascular complications in renal failure. J Am Soc Nephrol 2:1053-1062, 1991
27. 27. MENDALL MA, PATEL P, BALLAM L, STRACHAN D, NORTHFIELD TC: C-reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study. BMJ 312:1061-1065, 1996
28. 28. LIUZZO G, BIASUCCI LM, GALLIMORE JR, GRILLO R, REBUZZI AG, PEPYS MB, MASERI A: The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331:417-424, 1994
29. 29. THOMPSON SG, KIENAST J, PYKE SDM, HAVERKATE F, VAN DE LOO JCW: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332:635-641, 1995
30. 30. STEEL DM, WHITEHEAD AS: The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A. Immunol Today 15:81-87, 1994
31. 31. OWEN FO, LOWRIE EG: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 54:627-636, 1998
32. 32. DURRINGTON PN: How HDL protects against atheroma. Lancet 342:1315-1316, 1993
33. 33. HAHN R, OETTE K, MONDORF H, FINKE K, SIEBERTH HG: Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 48:279-288, 1993
34. 34. GRUNFELD C, GULLI R, MOSER AH, GAVIN LA, FEINGOLD KR: The effect of tumor necrosis factor administration in vivo on lipoprotein lipase activity in various tissues of the rat. J Lipid Res 30:579-585, 1989
35. 35. QUERFELD U, ONG JM, PREHN J: Effects of cytokines on the production of lipoprotein lipase in cultured human macrophages. J Lipid Res 31:1379-1386, 1990
36. 36. HEBERLIN A, NGUYEN AT, ZINGRAFF J, URENA P, DESCAMPS-LATSCHA B: Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor α. Kidney Int 37:116-125, 1990
37. 37. HEBERLIN A, URENA P, NGUYEN AT, ZINGRAFF J, DESCAMPS-LATSCHA B: Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 39:954-960, 1991
38. 38. ROSENSON RS: Myocardial injury: The acute phase response and lipoprotein metabolism. J Am Coll Cardiol 22:933-940, 1993
39. 39. COETZEE GA, STRACHAN AF, VAN DER WESTHUYZEN DR, HOPPE HC, JEENAH MS, DE BEER FC: Serum amyloid A-containing human high density lipoprotein 3 density, size, and apolipoprotein composition. J Biol Chem 261:9644-9651, 1986
40. 40. KISILEVSKY R: Serum amyloid A (SAA), a protein without a function: Some suggestions with reference to cholesterol metabolism. Med Hypotheses 35:337-341, 1991
41. 41. KRONENBERG F, UTERMANN G, DIEPLINGER H: Lipoprotein(a) in renal disease. Am J Kidney Dis 27:1-25, 1996
42. 42. KRONENBERG F, KÖNIG P, LHOTTA K, ÖFNER D, SANDHOLZER C, MARGREITER R, DOSCHE E, UTERMANN G, DIEPLINGER H: Apolipoprotein(a) associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb 14:1399-1404, 1994
43. 43. KARIO K, MATSUO T, KOBAYASHI H, MATSUO M, ASADA R, KOIDE M: High lipoprotein(a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. Thromb Haemostasis 74:1020-1025, 1995
44. 44. WADE DP, CLARKE JG, LINDAHL GE, LIU AC, ZYSOW BR, MEER K, SCHWARTZ K, LAWN RM: Genetic influences on lipoprotein(a) concentration. Biochem Soc Trans 21:499-502, 1993
45. 45. CHOLLET-MARTIN S, STAMATAKIS G, BAILLY S, MERY JP, GOUGEROT-POCIDALO MA: Induction of tumour necrosis factor-alpha during haemodialysis: Influence of the membrane type. Clin Exp Immunol 83:329-332, 1991
46. 46. ZAOUI P, HAKIM RM: The effects of the dialysis membrane on cytokine release. J Am Soc Nephrol 4:1711-1718, 1994
47. 47. HONKANEN E, GRONHAGEN-RISKA C, TEPPO AM, MAURY CP, MERI S: Acute-phase proteins during hemodialysis: Correlations with serum interleukin-1 beta levels and different dialysis membranes. Nephron 57:283-287, 1991
48. 48. STENVINKEL P, HEIMBÜRGER O, TUCK CH, BERGLUND L: Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int 53:1336-1342, 1998
49. 49. LAGRAND WK, NIESSEN HWM, WOLBINK G-J, JASPARS LH, VISSER CA, VERHEUGT FWA, MEIJER CJLM, HACK CE: C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation 95:97-103, 1997
50. 50. TORZEWSKI M, KLOUCHE M, HOCK J, MESSNER M, DORWEILER B, TORZEWSKI J, GABBERT HE, BHAKDI S: Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 18:369-378, 1998